Skip to main content

CRISPR gene-editing treatment could reach patients ‘very, very soon’: Intellia CEO

The trial success of CRISPR gene-editing technology has broad applications to treating other diseases, Intellia Therapeutics CEO John Leonard said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.